Qelbree (Viloxazine Extended-Release) for ADHD
Overview
Qelbree is a nonstimulant selective norepinephrine reuptake inhibitor with serotonin modulating activity, FDA-approved for treating ADHD in patients 6 years and older, including adults. 1
Dosing Guidelines
Pediatric Patients (6-11 years)
- Starting dose: 100 mg once daily 1
- Titration: Increase by 100 mg increments at weekly intervals 1
- Maximum dose: 400 mg once daily 1
- Median maintenance dose in clinical trials: 300 mg/day 2
Adolescents (12-17 years)
- Starting dose: 200 mg once daily 1
- Titration: After 1 week, may increase by 200 mg increment 1
- Maximum dose: 400 mg once daily 1
- Median maintenance dose in clinical trials: 400 mg/day 2
Adults
- Starting dose: 200 mg once daily 1
- Titration: Increase by 200 mg increments weekly 1
- Maximum dose: 600 mg once daily 1
- Mean dose in clinical trials: 504 mg/day, with 73% of patients using ≥400 mg/day during maintenance 3, 4
Administration
- Take once daily with or without food 1
- Capsules may be swallowed whole OR opened and sprinkled on pudding (consume within 15 minutes) or applesauce (consume within 2 hours) 1
- Do not cut, crush, or chew capsules 1
Dosage Adjustments
Severe Renal Impairment (eGFR <30 mL/min/1.73m²)
- Starting dose: 100 mg once daily 1
- Titration: 50-100 mg increments weekly 1
- Maximum dose: 200 mg once daily 1
Mild-to-Moderate Renal Impairment
- No dosage adjustment required 1
Contraindications
Absolute Contraindications
- Concomitant use with MAOIs or within 14 days of MAOI discontinuation 1
- Concomitant use with sensitive CYP1A2 substrates or CYP1A2 substrates with narrow therapeutic range 1
Boxed Warning: Suicidal Thoughts and Behaviors
Qelbree carries an FDA boxed warning for increased rates of suicidal ideation and behavior compared to placebo in clinical trials. 1
Required Monitoring
- Screen all patients prior to initiation for personal or family history of suicide, bipolar disorder, and depression 1
- Closely monitor all patients for clinical worsening and emergence of suicidal thoughts/behaviors throughout treatment 1
Common Adverse Effects
Pediatric Patients (6-17 years) - ≥5% and twice placebo rate
- Somnolence (9.5%) 1, 2
- Decreased appetite (6.0%) 1, 2
- Fatigue (5.7%) 1, 2
- Nausea 1
- Vomiting 1
- Insomnia 1
- Irritability 1
- Headache (8.9%) 2
- Nasopharyngitis (9.7%) 2
Adult Patients - ≥5% and twice placebo rate
- Insomnia (13.8-14.8%) 1, 3, 4
- Headache (9.0-10.7%) 1, 4
- Somnolence 1
- Fatigue (10.1-11.6%) 1, 4
- Nausea (10.1-13.8%) 1, 3, 4
- Decreased appetite (10.1%) 1, 4
- Dry mouth (9.0%) 1, 4
- Constipation 1
Discontinuation Rates
- Pediatric long-term study: 8.2% discontinued due to adverse events 2
- Adult short-term study: 9.0% discontinued due to adverse events (vs 4.9% placebo) 4
- Adult long-term study: 17.6% discontinued due to adverse events, most commonly insomnia (2.5%), nausea (2.5%), and fatigue (1.9%) 3
Severity Profile
- Most adverse events are mild to moderate; only 3.9% of pediatric patients reported any severe adverse event in long-term studies 2
Warnings and Precautions
Cardiovascular Effects
- Assess heart rate and blood pressure prior to initiation, after dose increases, and periodically during treatment 1
- Blood pressure and heart rate increases have been observed 1
Psychiatric Effects
- Screen for bipolar disorder before initiating treatment to avoid precipitating manic/hypomanic episodes 1
- Monitor for activation of mania or hypomania 1
Somnolence and Fatigue
- Advise patients to use caution when driving or operating machinery due to potential somnolence (including sedation and lethargy) and fatigue 1
Drug Interactions
CYP1A2 Interactions (Critical)
- Contraindicated with sensitive CYP1A2 substrates or those with narrow therapeutic range 1
- Not recommended for coadministration with moderate sensitive CYP1A2 substrates; dose reduction of the CYP1A2 substrate may be warranted if coadministration is necessary 1
MAOI Interactions
- Contraindicated with MAOIs or within 14 days of MAOI discontinuation 1
Efficacy Profile
Onset of Action
- Significant improvement observed within 1-2 weeks in both pediatric and adult populations 5, 4
- This represents a faster onset compared to atomoxetine (approximately 4 weeks) 5
Sustained Efficacy
- Improvements maintained for over 24 months in long-term extension studies 3, 2, 6
- Pediatric patients showed mean ADHD-RS-IV/5 total score improvement of -24.3 points at Month 3, -26.1 points at Month 12, and -22.4 points at last visit 2
- Adult patients demonstrated continued improvement throughout long-term treatment 3
Executive Function
- Significant improvements in executive function measured by BRIEF-A Global Executive Composite and Metacognition Index in adults 4
Clinical Positioning
Nonstimulant Alternative
- Qelbree is classified as a nonstimulant medication, useful for patients who do not respond to or cannot tolerate stimulant medications 5
- It is not listed in current Asian ADHD guidelines (2020-2024), which primarily recommend methylphenidate and atomoxetine 7
Combination Therapy
- Qelbree can be safely combined with psychostimulants in pediatric patients with inadequate stimulant response 8
- Combination therapy showed acceptable safety and tolerability with improvement in morning and evening ADHD behaviors and sleep disturbances 8
- Timing of administration (morning or evening) did not affect safety, efficacy, or sleep improvement 8
Common Pitfalls and Caveats
Dose Optimization
- Most adult patients (73%) require doses ≥400 mg/day for optimal maintenance treatment, with 36% using the maximum 600 mg/day dose 3
- Inadequate dosing is a common reason for treatment failure; ensure adequate titration to therapeutic doses 3, 4
Renal Impairment
- Do not overlook dose adjustment requirements in severe renal impairment (maximum 200 mg/day vs 400-600 mg/day in normal renal function) 1
Drug Interactions
- Always check for CYP1A2 substrate medications before prescribing to avoid contraindicated combinations 1